The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© Clarivate Analytics, Journal Citation Reports 2025
Journal Information
Full text access
¿El tolvaptán, un antagonista de los receptores de la vasopresina V2, ¿es un tratamiento eficaz para la hiponatremia euvolémica e hipervolémica?
Is tolvaptan (a vasopressin V2 receptor antagonist) effective in the management of isovolumic and hypervolaemic hypernatremia?
Visits
11452
F. Ortiz
This item has received
Article information
Full text is only available in PDF




